

- **Full Name:** Jeong Il Yu
 - **Current Position & Affiliation:** Associate Professor, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul
 - **Country:** Republic of Korea
-

• Educational Background:

- 1999~2005 MD at CHA University, College of Medicine (former School of Medicine, Pocheon Cha University)
- 2008~2012 Master's course and a degree The graduate school, Chungbuk National University, Chongju-si, Korea
- 2012~2017 Ph.D.'s course and a degree The graduate school, Sungkyunkwan University School of Medicine, Seoul, Korea

• Professional Experience:

- 2013~2015 Clinical fellow, Department of Radiation Oncology, Samsung Medical Center, Seoul
- 2015~2016 Instructor, Department of Radiation Oncology, Samsung Medical Center, Seoul
- 2016~2018 Clinical Assistant Professor, Department of Radiation Oncology Samsung Medical Center, Seoul
- 2019~2023 Assistant Professor, Department of Radiation Oncology, Sungkyunkwan University School of Medicine Samsung Medical Center, Seoul
- 2023~ Associate Professor, Department of Radiation Oncology, Sungkyunkwan University School of Medicine Samsung Medical Center, Seoul

• Professional Organizations:

- 2005.3: Member, Korean Medical Association (KMA)
- 2010.3: Member, Korean Society for Radiation Oncology (KOSRO)
- 2013.5: Member, Korean Cancer Association (KCA)
- 2013.5: Member, Korean Society of Medical Oncology (KSMO)
- 2013.5: Member, The Korean Liver Cancer Association (KLCA)

• Main Scientific Publications:

1. Yu JI, Choi C, Lee J, Kang WK, Park SH, Kim ST, et al. Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer: Analysis of the ARTIST phase III trial. *Radiother Oncol* 2020;152:19-25. <https://doi.org/10.1016/j.radonc.2020.07.043>.

2. Kim N, Yu JI, Lim DH, Lee J, Kim ST, Hong JY, et al. Prognostic Impact of Sarcopenia and Radiotherapy in Patients With Advanced Gastric Cancer Treated With Anti-PD-1 Antibody. *Front Immunol* 2021;12:701668. <https://doi.org/10.3389/fimmu.2021.701668>.
3. Kim N, Yu JI, Park HC, Yoo GS, Choi C, Hong JY, et al. Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab. *Cancer Immunol Immunother* 2021;70:1593-603. <https://doi.org/10.1007/s00262-020-02794-3>.
4. Kim K, Yu JI, Park HC, Yoo GS, Lim DH, Noh JM, et al. A phase II trial of hypofractionated high-dose proton beam therapy for unresectable liver metastases. *Radiother Oncol* 2022;176:9-16. <https://doi.org/10.1016/j.radonc.2022.09.003>.
5. Shin H, Yu JI, Park HC, Yoo GS, Cho S, Park JO, et al. The Feasibility of Stereotactic Body Proton Beam Therapy for Pancreatic Cancer. *Cancers (Basel)* 2022;14. <https://doi.org/10.3390/cancers14194556>.
6. Park SH, Lim DH, Sohn TS, Lee J, Zang DY, Kim ST, et al. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial(☆). *Ann Oncol* 2021;32:368-74. <https://doi.org/10.1016/j.annonc.2020.11.017>.